American Capital Management Inc. Sells 35,500 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

American Capital Management Inc. decreased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 19.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 147,800 shares of the medical research company’s stock after selling 35,500 shares during the quarter. American Capital Management Inc. owned 0.29% of Charles River Laboratories International worth $29,112,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tortoise Investment Management LLC boosted its stake in Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after acquiring an additional 57 shares during the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $32,000. Assetmark Inc. raised its stake in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after acquiring an additional 193 shares in the last quarter. Finally, Covestor Ltd increased its holdings in shares of Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock worth $65,000 after acquiring an additional 95 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of research reports. UBS Group increased their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. JPMorgan Chase & Co. downgraded Charles River Laboratories International from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $270.00 to $205.00 in a research note on Thursday, August 8th. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, The Goldman Sachs Group reduced their price target on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $214.38.

Charles River Laboratories International Stock Down 0.3 %

Shares of CRL stock opened at $199.06 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The stock has a market cap of $10.18 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 5.15 and a beta of 1.38. The firm’s 50-day moving average is $194.32 and its 200-day moving average is $204.95. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the company earned $2.72 earnings per share. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International announced that its board has initiated a share buyback plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).